Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 95 | BSPED2023 | Next issue

50th Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Manchester, UK
08 Nov 2023 - 10 Nov 2023

Card image cap
The 50th Annual BSPED Meeting will take place at the Midland Hotel, Manchester from 8-10 November 2023.

Poster Presentations

Diabetes 3

Previous section
Bone 2
Table of contents
Next section
Diabetes 4

ea0095p96 | Diabetes 3 | BSPED2023

EarLy Surveillance for Autoimmune type 1 diabetes (ELSA) – paediatric, general population screening in the UK

Choudhary Shivam , Quinn Lauren , Stanley David , Dias Renuka , Rashid R , Garstang J , Shukla D , Greenfield Sheila , Richter Alex , Narendran Parth

Background: Children with pre-symptomatic type 1 diabetes (T1D) can be identified through testing for circulating islet autoantibodies (AAb). Identifying children at risk reduces diabetic ketoacidosis at onset and allows participation in trials aiming to delay disease onset. Teplizumab is the first immunomodulatory agent licensed in the US to delay the onset of T1D by 3 years in individuals at risk; a licensing decision is awaited in the UK. The EarLy Surveill...
0 shares

ea0095p97 | Diabetes 3 | BSPED2023

Disparities in using an insulin pump to manage Type1 DM Evelina Children’s Hospital experience

Haj-Ahmed Eiman , Wiles Lillian , Cornish Michael , Regan Fiona

Introduction: In recent years there has been a highlight on the inequity of diabetes care and results across the UK. Research needs to be taken into barriers of access to technology for type 1 diabetes in CYP in the UK, specifically looking at provider bias, systemic issues within the health system, and individual and family factors.Aim of the study: We explored the potential factors that might affect access to technolog...
0 shares

ea0095p98 | Diabetes 3 | BSPED2023

Abstract withdrawn...
0 shares

ea0095p99 | Diabetes 3 | BSPED2023

Improving diabetes outcomes using an intensive structured education programme during first year of care after diagnosis

Burns Mark , Balasubrahmanyam Vani

Introduction: A diagnosis of type 1 diabetes makes a huge impact on the child and family. We believe intensive training in the first-year after diagnosis is crucial in laying a solid foundation to the lifelong management of this chronic condition. To provide this intensive support and drive reduction in HbA1c we started a quality improvement project focussing on the first year of care. Previously all patients were admitted following diagnosis of diabetes for s...
0 shares

ea0095p100 | Diabetes 3 | BSPED2023

The impact of COVID-19 and social deprivation on the outcomes of type 1 diabetes in children

Drage Rachel , Ahktar Fareen , Barrett Tim , Krone Ruth , Dias Renuka , Saraff Vrinda , Mohammed Zainab , Uday Suma , Idkoviak Jan , Drummond Lesley , Collins Louise , Leal Catarina , Kershaw Melanie

Introduction: The National Paediatric Diabetes Audit consistently highlights disparity in Type 1 diabetes outcomes with a higher mean HbA1c observed in the most deprived socioeconomic groups. During COVID concerns escalated as the impact of lockdowns on socioeconomic deprivation had potential to inflate pre-existing health divides. Our study aimed to assess care provided and impact of socioeconomic background on diabetes outcomes through COVID in a large terti...
2 shares

ea0095p101 | Diabetes 3 | BSPED2023

Creation of a simple, online ‘hello quiz’ for diabetes clinics- to help tailor appointments, improve communication, and aid service development

McNamara Claire , Brookes Claire , Harris Ruth , Robinson Kirsty , Sims Jack , Joshi Vineeta , Robinson Mark

Background: The NCYPDN plan describes a care model where children, young people (CYP) and families ‘co-design their care plan during appointments’ and ‘have a say in service planning.’ RCPCH ‘Voice Matters’ notes children want clinicians to ‘better understand how we are feeling, to ensure we’re involved in our treatment and have the support we need’. Our clinic experience found some CYP we...
0 shares

ea0095p102 | Diabetes 3 | BSPED2023

Prohormone convertase 1/3 deficiency can be associated with diabetes mellitus in childhood

Varughese Rachel , Howard Sasha , Butler Gary , Dattani Mehul

Prohormone convertase 1/3 (PC1/3) deficiency is rare, caused by homozygous or compound heterozygous mutations in the PCSK1 gene. PCSK1 encodes a serine protease important in cleavage of several proneuropeptides and prohormones. Despite a variety of known endocrine associations, paediatric diabetes mellitus is rare, described only once before. Previous understanding was that biological activity of elevated proinsulin (<5% of the activity of insulin) confers protection from ...
0 shares

ea0095p103 | Diabetes 3 | BSPED2023

Dietary intervention for the management of adolescent type 2 diabetes mellitus: A systematic review

Bhanot Alisha , Hawton Katherine , Perry Rachel , Hamilton-Shield Julian , Candler Toby

Introduction: Despite an increasing incidence of adolescent type 2 diabetes mellitus (T2DM) with its associated morbidities and poor long-term prognosis, there remains uncertainty in its management. The National Institute for Health and Clinical Excellence (NICE) currently recommends initial lifestyle modifications alongside pharmacology management with metformin. Despite being shown to be effective in adults, little is known about the impact of lifestyle inte...
0 shares

ea0095p104 | Diabetes 3 | BSPED2023

Sodium point of care testing at home in diabetes insipidus: A case report

Sharma Anika , Gan Hoong-wei

Patients with central diabetes insipidus (CDI) and concurrent hypothalamic adipsia can experience significant sodium fluctuations requiring prolonged, recurrent hospital admissions and frequent serum sodium testing. We report a case of a 13-year-old male with adipsic CDI where the use of a point of care sodium analyser at home to titrate fluid and desmopressin administration resulted in stabilisation of his serum sodium, prevention of unplanned hospital admissions and improvem...
1 shares

ea0095p105 | Diabetes 3 | BSPED2023

Management of diabetic ketoacidosis in 0 to 16 years presenting to the Southern Health and Social Care Trust between January 2020 and September 2022

Shah Shilpa , McVeigh Shane , Murphy Rebekah , Abdin Asma , Millar Sarinda

Introduction: Diabetic Ketoacidosis is a life threatening emergency. BSPED has updated their guideline with changes in the fluid management (bolus dose for shock, de-escalate early use of inotropes, percentage dehydration in moderate DKA and maximum weight)Aims: To determine the clinical features and outcome of new presentations of DKA in 0–16 year age range and audit fluid managementM...
0 shares

ea0095p106 | Diabetes 3 | BSPED2023

‘Getting it right from the start’ – A quality improvement project to reduce inequalities in access to diabetes related technology

Whittaker Rachel , Smith Julie

Background: The National Paediatric Diabetes Audit has identified inequalities in diabetes care. Children and young people (CYP) with Type 1 Diabetes Mellitus (T1DM) from both ethnic minority backgrounds and deprived areas are more likely to have reduced access to diabetes technologies and a higher HbA1c. In our service there was an inconsistent approach to the initiation of Continuous Glucose Monitoring (CGM) and use of insulin pumps. The introduction of a st...
0 shares

ea0095p107 | Diabetes 3 | BSPED2023

Levelling the Levemir: Are we prescribing too much long-acting insulin to children at diagnosis?

Gann Henry , Clarke Joely , Mitropoulou Eirini , Deamer Susannah , Andrews Edward , Knight Emma

Introduction: National guidance from the Association of Children’s Diabetes Clinicians (ACDC) recommends starting children with newly diagnosed type 1 diabetes mellitus on a total daily insulin dose of 0.5–0.75 iU per kilo per day (kg/d). This equates to a basal insulin dose of between 0.25–0.375 iU/kg per day. Local practice suggested many patients required a significantly smaller starting dose of basal insulin.Ai...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more